IPP Bureau
Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
By IPP Bureau - June 21, 2023
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
By IPP Bureau - June 21, 2023
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Croda opens technical centre in Hyderabad
By IPP Bureau - June 21, 2023
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals
By IPP Bureau - June 21, 2023
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
By IPP Bureau - June 20, 2023
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Zydus receives final approval from the USFDA for Minocycline Hydrochloride ER Tablets
By IPP Bureau - June 20, 2023
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Alkem Laboratories launches awareness initiative "Stop Sneeze to Wheeze"
By IPP Bureau - June 19, 2023
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
By IPP Bureau - June 19, 2023
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
By IPP Bureau - June 19, 2023
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants
By IPP Bureau - June 19, 2023
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
By IPP Bureau - June 19, 2023
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
By IPP Bureau - June 19, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Lupin launches Thiamine Hydrochloride Injection USP in the US
By IPP Bureau - June 19, 2023
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Lupin receives EIR from FDA for its API manufacturing facility in Vizag
By IPP Bureau - June 19, 2023
The inspection closed with the facility receiving an inspection classification of NAI
Merck completes acquisition of Prometheus Biosciences
By IPP Bureau - June 17, 2023
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
